品  名

貨  號

CAS 號

純  度

規  格

價格

Infliximab

(Avakine)

PHM220230

170277-31-3

90.30%

1 mg

￥1200

5 mg

￥3000

25 mg

￥7500

生物活性

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody thatspecifically 

binds to TNF-α.Infliximab prevents the interaction of TNF-α with TNF-α 

receptor  (TNFR1 and TNFR2).Infliximab has the potential for autoimmune, chronic 

inflammatory diseases and diabetic neuropathy research.

IC50 & Target

TNF-α

體外研究

(In Vitro)

TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated

glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by

significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab

restores phosphorylation of substrate-2 and AKT by attenuating

protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates

TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring

the insulin signalling pathway via PTP1B inhibition.

MCE has not independently confirmed the accuracy of these methods.

They are for reference only.

體內研究
(In Vivo)

A single injection of Infliximab (10 μg/g in 100 μl saline/dose ip) in diabetic

TNF-α+/+) mice leads to suppression of the increased serum TNF-α and

amelioration of the electrophysiological and biochemical deficits for at least 

4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root

ganglion is also attenuated by Infliximab.

MCE has not independently confirmed the accuracy of these methods.

They are for reference only.

CAS 號

170277-31-3

中文名稱

英夫利昔單抗

儲存方式

Please store the product under the recommended conditions in the Certificate

of Analysis.